Advicenne Launches IPO With Kidney Drug Close To Filing
Looking to raise up to €39.7m through a stock market listing, French firm Advicenne has been developing ADV7103, which could soon become the first drug to be approved for distal renal tubular acidosis.
You may also be interested in...
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard review for ADV7103 in dRTA patients and hopes to launch late 2020.
The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.